Flexible Stenting Solutions Inc. ("FSS"), a leading developer of next generation peripheral arterial and biliary stents, announced that it has received Conditional Investigational Device Exemption (IDE) approval for its FlexStent® Femoropopliteal Self Expanding Stent System. With this approval, FSS Read More...
EATONTOWN, N.J.--(Business Wire)--Flexible Stenting Solutions Inc. ("FSS"), a leading developer of next generationperipheral arterial and biliary stents, received 510(k) clearance for the FlexStent® Biliary Self Expanding Stent System.
The FlexStent® Biliary Self Expanding Stent System is indica Read More...
SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq:
MEND -
News) and privately held Flexible Stenting Solutions Inc. of Eatontown, N.J., today announced the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indicati Read More...
Cell Genesys, Inc. (Nasdaq: CEGE) and GBP IP, LLC, an affiliate of GBP Capital, the majority shareholder in privately held Lentigen Corporation, today announced that the two companies have entered into an asset sale agreement relating to Cell Genesys' lentiviral gene delivery technology, commonl Read More...
